<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227471</url>
  </required_header>
  <id_info>
    <org_study_id>VX16-445-001</org_study_id>
    <secondary_id>2017-000797-11</secondary_id>
    <nct_id>NCT03227471</nct_id>
  </id_info>
  <brief_title>A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human and proof-of-concept study of VX-445. The study includes 6 parts.
      Parts A, B, and C will be conducted in healthy subjects. Parts D, E, and F will be conducted
      in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del mutation of the CF
      transmembrane conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for
      the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ,
      IVA, or TEZ/IVA (F/MF genotypes).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">March 27, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>from baseline through safety follow-up (up to 10 days after last dose for Part A, B, and C)</time_frame>
    <description>Number of subjects with AEs and SAEs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>from baseline through safety follow-up (up to 35 days after last dose for Parts D, E, and F).</time_frame>
    <description>Number of subjects with AEs and SAEs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1) [Parts D, E, and F only]</measure>
    <time_frame>from baseline through Day 29</time_frame>
    <description>Absolute change in ppFEV1 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sweat chloride concentrations [Parts C, D, E, and F only]</measure>
    <time_frame>from baseline through Day 29</time_frame>
    <description>Absolute change in sweat chloride concentrations will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in ppFEV1 [Parts D, E, and F only]</measure>
    <time_frame>from baseline through Day 29</time_frame>
    <description>Relative change in ppFEV1 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score [Parts D, E, and F only]</measure>
    <time_frame>from baseline through Day 29</time_frame>
    <description>The absolute change in CFQ-R respiratory domain score will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of VX-445,TEZ and metabolites (M1-TEZ and M2-TEZ), IVA and metabolites (M1-IVA and M6-IVA) and VX-561</measure>
    <time_frame>from Day 1 through Day 43</time_frame>
    <description>Maximum plasma concentration [Cmax] will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-445, TEZ and metabolites (M1-TEZ and M2-TEZ), IVA and metabolites (M1-IVA and M6-IVA) and VX-561</measure>
    <time_frame>from Day 1 through Day 43</time_frame>
    <description>Area under the concentration versus time curve during a dosing interval (AUCtau) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-445, TEZ and metabolites (M1-TEZ and M2-TEZ), IVA and metabolites (M1-IVA and M6-IVA) and VX-561</measure>
    <time_frame>from Day 1 through Day 43</time_frame>
    <description>Trough plasma concentration [Ctrough] will be reported.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A: VX-445 in Healthy Subjects (HS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A includes single dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: VX-445 in HS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B includes multiple-dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-dose escalation of VX-445 in TC with TEZ/IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D1: F/MF genotypes TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 100 mg VX-445 qd in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D2: F/MF genotypes TC-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D2: F/MF genotypes TC-Mid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D2: F/MF genotypes TC-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: F/F genotype - TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: TEZ/IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F: F/MF genotypes - TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive VX-445 in TC with TEZ and VX-561 for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F: Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>150-mg IVA film-coated tablet for oral administration</description>
    <arm_group_label>Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <arm_group_label>Part D1: F/MF genotypes TC</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-High</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-Mid</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-Low</arm_group_label>
    <arm_group_label>Part E: F/F genotype - TC</arm_group_label>
    <arm_group_label>Part E: TEZ/IVA</arm_group_label>
    <other_name>VX-770</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ/IVA</intervention_name>
    <description>100-mg TEZ / 150-mg IVA fixed dose combination (FDC) tablet for oral administration.</description>
    <arm_group_label>Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <arm_group_label>Part D1: F/MF genotypes TC</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-High</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-Mid</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-Low</arm_group_label>
    <arm_group_label>Part E: F/F genotype - TC</arm_group_label>
    <arm_group_label>Part E: TEZ/IVA</arm_group_label>
    <other_name>VX-661/VX-770</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-445</intervention_name>
    <description>VX-445 tablet for oral administration.</description>
    <arm_group_label>Part A: VX-445 in Healthy Subjects (HS)</arm_group_label>
    <arm_group_label>Part B: VX-445 in HS</arm_group_label>
    <arm_group_label>Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <arm_group_label>Part D1: F/MF genotypes TC</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-High</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-Mid</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-Low</arm_group_label>
    <arm_group_label>Part E: F/F genotype - TC</arm_group_label>
    <arm_group_label>Part F: F/MF genotypes - TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebo</intervention_name>
    <description>Matched placebo.</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_label>Part C: Placebo</arm_group_label>
    <arm_group_label>Part D1: Placebo</arm_group_label>
    <arm_group_label>Part D2: F/MF genotypes TC-Low</arm_group_label>
    <arm_group_label>Part D2: Placebo</arm_group_label>
    <arm_group_label>Part E: TEZ/IVA</arm_group_label>
    <arm_group_label>Part F: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ</intervention_name>
    <description>50-mg tablet for oral administration.</description>
    <arm_group_label>Part F: F/MF genotypes - TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-561</intervention_name>
    <description>50-mg tablet for oral administration.</description>
    <arm_group_label>Part F: F/MF genotypes - TC</arm_group_label>
    <other_name>CTP-656</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Parts A, B, and C:

          -  Female subjects must be of non-childbearing potential.

          -  Between the ages of 18 and 55 years, inclusive.

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and a total body weight &gt;50 kg

        Parts D, E, and F:

          -  Body weight ≥35 kg.

          -  Subjects must have an eligible CFTR genotype:

               -  Parts D and F: Heterozygous for F508del and an MF mutation (F/MF)

               -  Part E: Homozygous for F508del (F/F)

          -  FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height.

        Key Exclusion Criteria:

        Parts A, B, and C:

          -  Any condition possibly affecting drug absorption.

          -  History of febrile illness within 14 days before the first study drug dose.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

        Parts D, E, and F:

          -  History of clinically significant cirrhosis with or without portal hypertension.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status.

          -  History of solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Children's Healthcare</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Kaiser Permanente) Oakland Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>96411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital Cardiac and Lung Transplant Clinic</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Services at North Druid Hills</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc., Evansville Clinic [Parts A, B, C only]</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minn</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico School of Medicine</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health Office of Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center/Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Children's Chest Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Adult Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis van den Haag</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

